Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into routine care remains limited. Opportunely, several implementation studies and programs have been initiated over recent years. This article presents an overview of these studies and identifies current research gaps. Importantly, one such gap is the undetermined collective clinical utility of implementing a panel of PGx‐markers into routine care, because the evidence base is currently limited to specific, individual drug‐gene pairs. The Ubiquitous Pharmacogenomics (U‐PGx) Consortium, which has been funded by the European Commission's Horizon‐2020 program, aims to address this unmet need. In a prospective, block‐randomized, controlled clinical study (PREemptive Pharmacogenomic testing for prevention of Adverse drug REactions [PREPARE]), pre‐emptive genotyping of a panel of clinically relevant PGx‐markers, for which guidelines are available, will be implemented across healthcare institutions in seven European countries. The impact on patient outcomes and cost‐effectiveness will be investigated. The program is unique in its multicenter, multigene, multidrug, multi‐ethnic, and multihealthcare system approach.

[1]  N J Cox,et al.  The 1200 Patients Project: Creating a New Medical Model System for Clinical Implementation of Pharmacogenomics , 2012, Clinical pharmacology and therapeutics.

[2]  Gianrico Farrugia,et al.  Multidisciplinary Model to Implement Pharmacogenomics at the Point of Care , 2016, Genetics in Medicine.

[3]  M. Adamek,et al.  Quantitative diagnostics of gill diseases in common carp: not as simple as it seems. , 2019, Diseases of aquatic organisms.

[4]  L. Härmark,et al.  Web-based intensive monitoring of adverse events following influenza vaccination in general practice. , 2015, Vaccine.

[5]  Joseph Finkelstein,et al.  Potential utility of precision medicine for older adults with polypharmacy: a case series study , 2016, Pharmacogenomics and personalized medicine.

[6]  A L Fuhlbrigge,et al.  Economic Evaluation of Pharmacogenetic Tests , 2008, Clinical pharmacology and therapeutics.

[7]  M. Relling,et al.  Concordance of DMET Plus Genotyping Results With Those of Orthogonal Genotyping Methods , 2012, Clinical pharmacology and therapeutics.

[8]  Matthias Samwald,et al.  Examining perceptions of the usefulness and usability of a mobile-based system for pharmacogenomics clinical decision support: a mixed methods study , 2016, PeerJ.

[9]  S. Mallal,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.

[10]  M. Pirmohamed,et al.  Pharmacogenetic tests: the need for a level playing field , 2012, Nature Reviews Drug Discovery.

[11]  Soma Das,et al.  Adoption of a clinical pharmacogenomics implementation program during outpatient care–initial results of the University of Chicago “1,200 Patients Project” , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[12]  Megan Doerr,et al.  Cleveland Clinic's Center for personalized healthcare: setting the stage for value-based care. , 2014, Pharmacogenomics.

[13]  T. Skaar,et al.  Implementation of a pharmacogenomics consult service to support the INGENIOUS trial , 2016, Clinical pharmacology and therapeutics.

[14]  Nicole A. Restrepo,et al.  Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records. , 2013, Pharmacogenomics.

[15]  Ching-Hon Pui,et al.  PG4KDS: A model for the clinical implementation of pre‐emptive pharmacogenetics , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[16]  M. Khoury.  Dealing With the Evidence Dilemma in Genomics and Personalized Medicine , 2010, Clinical pharmacology and therapeutics.

[17]  E. Basch,et al.  Patient-reported outcomes in the evaluation of toxicity of anticancer treatments , 2016, Nature Reviews Clinical Oncology.

[18]  M. Samwald,et al.  A brighter future for the implementation of pharmacogenomic testing , 2016, European Journal of Human Genetics.

[19]  T. Klein,et al.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network , 2011, Clinical pharmacology and therapeutics.

[20]  H. Guchelaar,et al.  Pharmacogenetics in the Cancer Clinic: From Candidate Gene Studies to Next‐Generation Sequencing , 2014, Clinical pharmacology and therapeutics.

[21]  R. Altman,et al.  Pharmacogenomics: “Noninferiority” Is Sufficient for Initial Implementation , 2011, Clinical pharmacology and therapeutics.

[22]  R. Altman,et al.  Pharmacogenomics: will the promise be fulfilled? , 2011, Nature Reviews Genetics.

[23]  Julie A Johnson,et al.  Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. , 2013, Pharmacogenomics.

[24]  Christopher G Chute,et al.  Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. , 2014, Mayo Clinic proceedings.

[25]  Julia M. Barbarino,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing , 2015, Clinical pharmacology and therapeutics.

[26]  L Gong,et al.  The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy , 2012, Clinical pharmacology and therapeutics.

[27]  M. Lee,et al.  Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study , 2015, BMJ : British Medical Journal.

[28]  Erica A. Bowton,et al.  Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing , 2013, Clinical pharmacology and therapeutics.

[29]  Joo-Youn Cho,et al.  Targeted Next‐Generation Sequencing for Comprehensive Genetic Profiling of Pharmacogenes , 2017, Clinical pharmacology and therapeutics.

[30]  M. Relling,et al.  Development and use of active clinical decision support for preemptive pharmacogenomics , 2013, Journal of the American Medical Informatics Association : JAMIA.

[31]  L. Trümper.  From bench to bedside , 2005, Medizinische Klinik.

[32]  William E. Evans,et al.  Pharmacogenomics in the clinic , 2015, Nature.

[33]  D. Flockhart,et al.  Pharmacogenomically actionable medications in a safety net health care system , 2016, SAGE open medicine.

[34]  Kelly L. Scolaro,et al.  Transitioning Pharmacogenomics into the Clinical Setting: Training Future Pharmacists , 2016, Front. Pharmacol..

[35]  Charis Eng,et al.  Implementation of Clinical Pharmacogenomics within a Large Health System: From Electronic Health Record Decision Support to Consultation Services , 2016, Pharmacotherapy.

[36]  R. Altman,et al.  Implementing Personalized Medicine: Development of a Cost‐Effective Customized Pharmacogenetics Genotyping Array , 2012, Clinical pharmacology and therapeutics.

[37]  R. Altman,et al.  Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. , 2010, The Lancet. Oncology.

[38]  Suzette J. Bielinski,et al.  Design and Anticipated Outcomes of the eMERGE-PGx Project: A Multi-Center Pilot for Pre-Emptive Pharmacogenomics in Electronic Health Record Systems , 2014, Clinical pharmacology and therapeutics.

[39]  E. Clayton,et al.  Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project , 2012, Clinical pharmacology and therapeutics.

[40]  J. Kelsoe,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Carbamazepine Dosing , 2012, Clinical pharmacology and therapeutics.

[41]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing , 2014 .

[42]  Rita Barallon,et al.  A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. , 2013, The New England journal of medicine.

[43]  A. Shuldiner,et al.  Educational innovations in clinical pharmacogenomics , 2016, Clinical pharmacology and therapeutics.

[44]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.

[45]  Chen-Yang Shen,et al.  Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. , 2011, The New England journal of medicine.

[46]  E. Basch,et al.  Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. , 2016, Clinical therapeutics.

[47]  Diane Hauser,et al.  The IGNITE network: a model for genomic medicine implementation and research , 2015, BMC Medical Genomics.

[48]  Jeffrey C. Hall,et al.  The CLIPMERGE PGx Program: Clinical Implementation of Personalized Medicine Through Electronic Health Records and Genomics–Pharmacogenomics , 2013, Clinical pharmacology and therapeutics.

[49]  B. Carleton,et al.  Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine , 2016, Pediatric Drugs.

[50]  Munir Pirmohamed,et al.  A Randomized Trial of Genotype-Guided Dosing of Warfarin , 2014 .

[51]  M. Ingelman-Sundberg,et al.  Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response , 2016, Genetics in Medicine.

[52]  L. Gong,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon‐α–Based Regimens , 2014, Clinical pharmacology and therapy.

[53]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte , 2008, Clinical pharmacology and therapeutics.

[54]  M. Pirmohamed,et al.  Development and Inter-Rater Reliability of the Liverpool Adverse Drug Reaction Causality Assessment Tool , 2011, PloS one.

[55]  Henk-Jan Guchelaar,et al.  Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease. , 2015, Gastroenterology.

[56]  Personalized Medicine: Building the GPS to Take Us There , 2007, Clinical pharmacology and therapeutics.

[57]  J J Swen,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants , 2013, Clinical pharmacology and therapy.

[58]  M. Whirl‐Carrillo,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing , 2016, Clinical pharmacology and therapeutics.

[59]  Bernadine Brady,et al.  A MIXED-METHODS STUDY , 2019 .

[60]  T. Doksum,et al.  Integrating Molecular Medicine into the US Health‐care System: Opportunities, Barriers, and Policy Challenges , 2007, Clinical pharmacology and therapeutics.

[61]  M. Ingelman-Sundberg,et al.  Genetic variation in the human cytochrome P450 supergene family , 2015, Pharmacogenetics and genomics.

[62]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype , 2012, Clinical pharmacology and therapeutics.

[63]  Jennifer Abbasí.  Getting Pharmacogenomics Into the Clinic. , 2016, JAMA.

[64]  J. Downing,et al.  Comparison of genome sequencing and clinical genotyping for pharmacogenes , 2016, Clinical pharmacology and therapeutics.

[65]  Teri E Klein,et al.  Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. , 2015, Annual review of pharmacology and toxicology.

[66]  Munir Pirmohamed,et al.  Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. , 2014, Annual review of genomics and human genetics.

[67]  Kristin A. Maloney,et al.  The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real‐World Implementation , 2013, Clinical pharmacology and therapeutics.

[68]  R. Weinshilboum,et al.  Pharmacogenomics: Bench to bedside. , 2005, Discovery medicine.

[69]  A. Wu.  Pharmacogenomic testing and response to warfarin , 2015, The Lancet.

[70]  W. Burke,et al.  Pharmacogenetic testing: not as simple as it seems , 2008, Genetics in Medicine.

[71]  M. Relling,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype , 2014, Clinical pharmacology and therapeutics.

[72]  E. McDonagh,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype , 2014, Clinical pharmacology and therapy.

[73]  Melissa A. Basford,et al.  The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future , 2013, Genetics in Medicine.

[74]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.

[75]  K. Sangkuhl,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors , 2015, Clinical pharmacology and therapy.

[76]  Teri E. Klein,et al.  Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC) , 2016, J. Am. Medical Informatics Assoc..

[77]  M. Whirl‐Carrillo,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing , 2011, Clinical pharmacology and therapeutics.

[78]  H. Rocca.  Towards personalized medicine , 2014 .

[79]  G. Ginsburg,et al.  The path to personalized medicine. , 2002, Current opinion in chemical biology.

[80]  M. Guyer,et al.  Charting a course for genomic medicine from base pairs to bedside , 2011, Nature.

[81]  Joseph L. Kannry,et al.  Physician Attitudes toward Adopting Genome-Guided Prescribing through Clinical Decision Support , 2014, Journal of personalized medicine.

[82]  R B Altman,et al.  The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response , 2007, Clinical pharmacology and therapeutics.

[83]  Henk-Jan Guchelaar,et al.  Translating Pharmacogenomics: Challenges on the Road to the Clinic , 2007, PLoS medicine.